Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dolutegravir Dispersible Tablets vs Granules
NCT02185300Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by ViiV Healthcare. Primary endpoints: Composite of pharmacokinetic (PK) parameters following single dose administration of DTG 20 mg DT dispersed in LMC water at Day 3, Composite of pharmacokinetic (PK) parameters following single dose administration of DTG 20 mg DT dispersed in CONTREX mineral water at Day 3 and 1 more. Started Jul 2014; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02185300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02185300.